RT Journal Article
T1 Antibody Responses to Fusobacterium nucleatum Proteins in Prediagnostic Blood Samples are not Associated with Risk of Developing Colorectal Cancer.
A1 Butt, Julia
A1 Jenab, Mazda
A1 Pawlita, Michael
A1 Overvad, Kim
A1 Tjonneland, Anne
A1 Olsen, Anja
A1 Boutron-Ruault, Marie-Christine
A1 Carbonnel, Franck
A1 Mancini, Francesca Romana
A1 Kaaks, Rudolf
A1 Kühn, Tilman
A1 Boeing, Heiner
A1 Trichopoulou, Antonia
A1 Karakatsani, Anna
A1 Palli, Domenico
A1 Pala, Valeria Maria
A1 Tumino, Rosario
A1 Sacerdote, Carlotta
A1 Panico, Salvatore
A1 Bueno-de-Mesquita, Bas
A1 van Gils, Carla H
A1 Vermeulen, Roel C H
A1 Weiderpass, Elisabete
A1 Quirós, José Ramón
A1 Duell, Eric Jeffrey
A1 Sanchez-Perez, Maria-Jose
A1 Dorronsoro, Miren
A1 Huerta, José María
A1 Ardanaz, Eva
A1 Van Guelpen, Bethany
A1 Harlid, Sophia
A1 Perez-Cornago, Aurora
A1 Gunter, Marc J
A1 Murphy, Neil
A1 Freisling, Heinz
A1 Aune, Dagfinn
A1 Waterboer, Tim
A1 Hughes, David J
AB There is a lack of prospective data on the potential association of Fusobacterium nucleatum (F. nucleatum) and colorectal cancer risk. In this study, we assessed whether antibody responses to F. nucleatum are associated with colorectal cancer risk in prediagnostic serum samples in the European Prospective Investigation into Nutrition and Cancer (EPIC) cohort. We applied a multiplex serology assay to simultaneously measure antibody responses to 11 F. nucleatum antigens in prediagnostic serum samples from 485 colorectal cancer cases and 485 matched controls. Conditional logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CI). We observed neither a statistically significant colorectal cancer risk association for antibodies to individual F. nucleatum proteins nor for combined positivity to any of the 11 proteins (OR, 0.81; 95% CI, 0.62-1.06). Antibody responses to F. nucleatum proteins in prediagnostic serum samples from a subset of colorectal cancer cases and matched controls within the EPIC study were not associated with colorectal cancer risk. Our findings in prospectively ascertained serum samples contradict the existing literature on the association of F. nucleatum with colorectal cancer risk. Future prospective studies, specifically detecting F. nucleatum in stool or tissue biopsies, are needed to complement our findings.
YR 2019
FD 2019
LK http://hdl.handle.net/10668/14470
UL http://hdl.handle.net/10668/14470
LA en
DS RISalud
RD Apr 10, 2025